HUTCHMED (China) LtdNASDAQ:HCM
- LAST PRICE21.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots20.0000/ 10
- Ask / Lots21.7500/ 5
- Open / Previous Close0.0000 / 21.4000
- Day Range---
- 52 Week Range
- Volume2
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HCM |
|---|---|---|
| 09:32 ET | 759 | 21.79 |
| 09:34 ET | 100 | 21.37 |
| 09:36 ET | 219 | 21.42 |
| 09:39 ET | 400 | 21.57 |
| 09:41 ET | 562 | 21.54 |
| 09:45 ET | 300 | 21.48 |
| 09:48 ET | 1500 | 21.4434 |
| 09:50 ET | 100 | 21.46 |
| 09:52 ET | 100 | 21.44 |
| 09:54 ET | 200 | 21.52 |
| 09:57 ET | 100 | 21.46 |
| 09:59 ET | 100 | 21.465 |
| 10:01 ET | 505 | 21.4 |
| 10:03 ET | 200 | 21.4 |
| 10:06 ET | 1300 | 21.42 |
| 10:08 ET | 975 | 21.42 |
| 10:10 ET | 180 | 21.44 |
| 10:15 ET | 100 | 21.42 |
| 10:17 ET | 300 | 21.45 |
| 10:19 ET | 200 | 21.43 |
| 10:21 ET | 300 | 21.4 |
| 10:26 ET | 100 | 21.35 |
| 10:30 ET | 200 | 21.315 |
| 10:33 ET | 100 | 21.31 |
| 10:35 ET | 664 | 21.46 |
| 10:39 ET | 100 | 21.385 |
| 10:46 ET | 100 | 21.35 |
| 10:53 ET | 100 | 21.35 |
| 10:55 ET | 5928 | 21.45 |
| 10:57 ET | 6675 | 21.545 |
| 11:00 ET | 143 | 21.525 |
| 11:02 ET | 100 | 21.495 |
| 11:08 ET | 100 | 21.46 |
| 11:09 ET | 100 | 21.45 |
| 11:13 ET | 110 | 21.45 |
| 11:15 ET | 100 | 21.5 |
| 11:20 ET | 200 | 21.39 |
| 11:26 ET | 715 | 21.465 |
| 11:33 ET | 100 | 21.46 |
| 11:36 ET | 109 | 21.45 |
| 11:38 ET | 530 | 21.51 |
| 11:42 ET | 100 | 21.47 |
| 11:47 ET | 100 | 21.44 |
| 11:51 ET | 100 | 21.48 |
| 12:02 ET | 1095 | 21.45 |
| 12:07 ET | 100 | 21.45 |
| 12:16 ET | 295 | 21.45 |
| 12:21 ET | 113 | 21.445 |
| 12:25 ET | 414 | 21.41 |
| 12:30 ET | 706 | 21.35 |
| 12:36 ET | 200 | 21.36 |
| 12:59 ET | 100 | 21.34 |
| 01:10 ET | 100 | 21.3 |
| 01:14 ET | 100 | 21.31 |
| 01:15 ET | 1133 | 21.33 |
| 01:28 ET | 115 | 21.3 |
| 01:32 ET | 213 | 21.36 |
| 01:46 ET | 100 | 21.37 |
| 01:51 ET | 100 | 21.33 |
| 02:02 ET | 100 | 21.32 |
| 02:04 ET | 918 | 21.36 |
| 02:06 ET | 500 | 21.4 |
| 02:08 ET | 1750 | 21.375 |
| 02:09 ET | 1017 | 21.4 |
| 02:11 ET | 3725 | 21.39 |
| 02:15 ET | 3785 | 21.43 |
| 02:18 ET | 200 | 21.45 |
| 02:24 ET | 233 | 21.45 |
| 02:27 ET | 500 | 21.46 |
| 02:29 ET | 300 | 21.4775 |
| 02:31 ET | 300 | 21.45 |
| 02:40 ET | 100 | 21.43 |
| 02:44 ET | 100 | 21.42 |
| 02:51 ET | 100 | 21.39 |
| 02:54 ET | 100 | 21.36 |
| 03:00 ET | 117 | 21.34 |
| 03:02 ET | 100 | 21.3689 |
| 03:03 ET | 2113 | 21.38 |
| 03:09 ET | 300 | 21.4 |
| 03:12 ET | 106 | 21.385 |
| 03:18 ET | 100 | 21.39 |
| 03:21 ET | 112 | 21.36 |
| 03:23 ET | 100 | 21.36 |
| 03:25 ET | 315 | 21.38 |
| 03:27 ET | 4563 | 21.39 |
| 03:30 ET | 816 | 21.4 |
| 03:34 ET | 200 | 21.41 |
| 03:36 ET | 616 | 21.45 |
| 03:38 ET | 200 | 21.45 |
| 03:41 ET | 600 | 21.42 |
| 03:43 ET | 400 | 21.405 |
| 03:45 ET | 309 | 21.39 |
| 03:48 ET | 213 | 21.36 |
| 03:50 ET | 100 | 21.39 |
| 03:52 ET | 1500 | 21.41 |
| 03:54 ET | 418 | 21.41 |
| 03:56 ET | 1330 | 21.38 |
| 03:57 ET | 862 | 21.39 |
| 03:59 ET | 1658 | 21.4 |
May 13, 2024
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Na ve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui, from 8:00PM ET on Monday May 13, 2024 by Dow Jones
8:00PM ET on Monday May 13, 2024 by Dow JonesHUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China, from 8:00PM ET on Monday May 13, 2024 by Dow Jones
8:00PM ET on Monday May 13, 2024 by Dow Jones
May 8, 2024
Press Release: HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee, from 4:30AM ET on Wednesday May 08, 2024 by Dow Jones
4:30AM ET on Wednesday May 08, 2024 by Dow JonesHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee, from 4:30AM ET on Wednesday May 08, 2024 by Dow Jones
4:30AM ET on Wednesday May 08, 2024 by Dow Jones
Apr 26, 2024
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda, from 8:30AM ET on Friday Apr 26, 2024 by Dow Jones
8:30AM ET on Friday Apr 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HUTCHMED (China) Ltd | 3.8B | 37.2x | --- |
Prestige Consumer Healthcare Inc | 3.5B | -43.5x | --- |
Amphastar Pharmaceuticals Inc | 2.0B | 14.2x | --- |
Corcept Therapeutics Inc | 2.9B | 25.9x | +9.80% |
Pacira Biosciences Inc | 1.4B | 23.8x | --- |
Tilray Brands Inc | 1.7B | -4.2x | --- |
Company Information
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Contact Information
- Headquarters
- 48Th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong
- Phone
- ---
- Fax
- ---
Executives
- Executive Chairman of the Board
- Chi Keung To
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Weiguo Su
- Chief Financial Officer, Executive Director
- Chig Fung Cheng
- Chief Operating Officer, Executive Vice President
- Karen Atkin
- Executive Vice President and Chief Commercial Officer, China
- Hong Chen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.8B |
|---|---|
Revenue (TTM) | $838.0M |
Shares Outstanding | 174.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $0.57 |
Book Value | $4.19 |
P/E Ratio | 37.2x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 35.2x |
Operating Margin | 2.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
